Loading...
Market
What will be the next milestone for Wave Life Sciences' RestorAATion-2 trial by June 2025?
2
Resolution / Starting Odds
Phase 3 trial initiation • 25%
FDA breakthrough therapy designation • 25%
Partnership with a major pharma • 25%
Other milestone • 25%
Official press releases from Wave Life Sciences
Story
Wave Life Sciences Surges 55% After Achieving First-Ever Therapeutic RNA Editing in RestorAATion-2 Trial
Oct 16, 2024, 12:32 PM
Wave Life Sciences announced a significant milestone in RNA editing, achieving the first-ever therapeutic RNA editing in humans. The breakthrough was achieved in the RestorAATion-2 trial of WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD). A single subcutaneous dose of WVE-006 in the first two patients with homozygous 'ZZ' AATD resulted in mean plasma total AAT levels of approximately 11 micromolar, with mean wild-type M-AAT representing 6% of the total. This development led to a 55% surge in Wave Life Sciences' stock price. Additionally, the company has announced a Virtual Research Day on October 30, 2024.
View original story
Similar markets
Yes • 50%
No • 50%
Neurological Disorders • 25%
Genetic Diseases • 25%
Oncology • 25%
Other • 25%
Huntington's Disease • 25%
ALS • 25%
Duchenne Muscular Dystrophy • 25%
Other • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Announces new clinical trial • 25%
Announces new partnership • 25%
Announces new funding • 25%
No significant announcements • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Regulatory approval submission • 25%
No significant milestone • 25%
Less than 50% efficacy • 25%
50-69% efficacy • 25%
70-89% efficacy • 25%
90% or higher efficacy • 25%
Highly positive • 25%
Moderately positive • 25%
Neutral • 25%
Negative • 25%
BLA submission • 25%
Phase III trial initiation • 25%
Conditional approval • 25%
No progress • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%